Introduction
Tuberculosis (TB) is a major cause of illness and death worldwide, especially in Asia and Africa. The World Health Organization (WHO) estimates that 9.2 million new cases of TB occurred in 2006 (139 per 100,000 population). Asia (South-East Asia and Western Pacific regions) accounts for 55% of global cases, and Africa accounts for 31%. Among the 9.2 million new cases of TB in 2006, 4.1 million were new smear-positive cases (44%) and 0.7 million human immunodeficiency virus (HIV)-positive cases (8%). The global incidence peaked around 2003, but has now stabilized. However, because of population growth in Asia, Africa and Europe, the number of new cases was still increasing between 2005 and 2006-from 9.1 million to 9.2 million. 1 In addition, multidrug resistant (MDR)-TB, which is resistant to isoniazid (INH) and rifampin (RIF), emerged worldwide. The WHO estimated the number of incident MDR-TB cases was 489,139 in 2006. Three countries, China, India, and Russia, accounted approximately 50% of the global burden of MDR-TB. 2 A notification system for TB cases was established in Taiwan in July 1997; if there were any suspected TB cases reported to the public health administration, the hospital would not receive any reimbursement from the National Health Insurance. Because of this, more TB cases have been identified. 3 In 2006, the Centers for Disease Control (CDC)
of Taiwan reported 15,378 newly diagnosed TB cases. An incidence of 67.4 cases per 100,000 population and a mortality rate of 3.6 deaths per 100,000 population were reported. 4 The incidence was higher in aborigines and in people living in mountainous counties or regions.
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INH was introduced for TB treatment in 1952 and RIF in 1978. In Taiwan, drug-resistant pulmonary TB has been reported since 1962. 6 
Laboratory procedures
All drug susceptibility tests were performed in the mycobacteriology laboratory of the Changhua Christian Hospital. Prior to the end of 2004, the digested and decontaminated specimens were inoculated into a Mycobacteria Growth Indicator Tube (MGIT) and placed into the BACTEC MGIT 960 system (Becton Dickinson, Sparks, MD, USA) for culture. Since the end of 2004, in addition to the MGIT 960 system, the specimens were cultured on Löwenstein-Jensen media. After the identification of MTBC, a BACTEC MGIT 960 SIRE kit was used for antimicrobial susceptibility testing (AST) prior to March 1, 2005 . Critical concentrations of INH (0.1 μg/mL), RIF (1.0 μg/mL), EMB (5.0 μg/mL), and streptomycin (1.0 μg/ mL) were tested. After March 1, 2005, this method was replaced by the agar proportion method. Middlebrook 7H10 agar was used for AST, containing the standard sensitive strain, H37Rv, for quality control. The media comprised were 0.2 μg/mL INH, 1.0 μg/mL RIF, 5.0 μg/mL EMB and 2.0 μg/mL streptomycin. Organisms were considered resistant to a given drug if any growth ≥ 1% of the drug free control was observed. Primary resistance was defined as the presence of drug resistance in new cases, or in patients who had received anti-TB treatment for < 1 month. Drug resistance among previously treated cases was defined as resistance in patients who had already received anti-TB therapy for ≥ 1 month, or were retreated. Combined resistance was defined as any resistance regardless of previous treatment. MDR-TB was resistant to INH and RIF.
Statistical analysis
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Differences in drug resistance between different age groups, sexes, or previous anti-TB treatment were analyzed using the χ 2 test or
Fisher's exact test. Trends in drug resistance were evaluated by logistic regression analysis. A p value of < 0.05 was considered statistically significant.
Results
During the 5-year study period, 92,808 specimens submitted for mycobacterial cultures from inpatient and outpatient services and yielded 4,945 isolates of MTBC (positive rate, 5.3%). Table 1 . A significant decrease in the resistance rates to the first-line drugs, or any drug, was noted (p < 0.05). The decreasing trend was significant, especially after 2006 (p = 0.009 and p = 0.034 for any drug resistance; Table 2 ). A comparison of drug resistance between patients with and without previous anti-TB therapy is shown in Table 3 . Higher resistance rates to INH, RIF, EMB, streptomycin, and higher MDR was seen in those patients that had been previously treated (p < 0.05).
The drug resistance was reviewed by sex and age ( Table 4 ). The overall drug resistant rate was higher in those aged 45-64 years (25.2%), followed by those aged 25-44 years (19.6%), those aged < 25 years (18.8%), and those aged ≥ 65 years (17.0%). MDR-TB was highest among the group aged 25-44 years (4.5%) compared with the groups aged 45-64 years (3.5%) and ≥ 65 years (1.2%). The drug resistant rate was similar in male (19.3%) and female (18.8%) patients (p = 0.778). However, a significant difference was noted (p = 0.003) between the different age groups.
Of the 1,961 patients, an HIV screening test was available for 222 (11.3%) patients. Of these, seven (3.2%) patients had HIV infection as confirmed by Western blot. Sixty-five patients had been tested for HIV antibody before diagnosis of TB, and four were HIV-positive. The remaining 157 patients were tested for HIV antibody after TB diagnosis, and three (1.9%) were HIV-seropositive.
Discussion
The WHO reported that the global incidence of TB peaked around 2003 and appeared to stabilize, or began to decline. However, the number of new cases increased between 2005 and 2006. 1 The estimated TB burden varied in different countries. In 2006, the estimated incidence in Taiwan, calculated from the WHO equation, was 87 per 100,000 per year; and the estimated prevalence was 113 per 100,000 per year. 4 The results were similar to those of Republic of Korea, but higher than those in Hong Kong (incidence of 62 per 100,000 per year; prevalence of 64 per 100,000 per year) and Singapore (incidence of 26 per 100,000 per year; prevalence of 25 per 100,000 per year).
In Taiwan The Global Project on Anti-Tuberculosis Drug Resistance Surveillance was initiated in 1994. 10, 11 In new cases of TB, the median prevalence of resistance to any drug during 2002-2007 was 11.1%, and to MDR was 1.6%. 10 The prevalence of MDR among new cases ranged from 0% in eight countries to 22.3% in Baku and Azerbaijan. In previously treated cases, the median prevalence of resistance to any drug was 25.1% and to MDR was 11.7%. This study revealed that the drug resistance rate at this hospital in central Taiwan was close to the global median rate. Compared with the resistance rate in Hong Kong (11.1% any drug and 0.9% MDR in new cases) and Singapore (6.5% any drug and 0.2% MDR in new cases), this study showed higher drug resistance rates, whereas the resistance rates were lower than that in the Republic of Korea. The combined resistance reported in Taiwan from 1982 to 2004 was: INH = 13.9-35.9%, RIF = 4.9-18.2%, EMB = 4.1-15.7%, streptomycin = 8.3-28.6% and MDR = 3.9-17.3%. From recent reports, 12-15 the combined resistance to any drug was 23.4% in northern Taiwan, 52.4% in southern Taiwan and 28.6% in eastern Taiwan. The combined resistance to any drug in this study was much lower than that in northern, southern and eastern Taiwan. In addition, the overall drug resistance of individual firstline drugs in this study was lower than that in previous studies, 12, 13, 15 except for the overall drug resistance to streptomycin, which was lower in eastern Taiwan. This finding was the same for MDR-TB. Overall, drug resistance was lower at this hospital than in other regions. This may be due to a smaller number of TB cases in central Taiwan and certain patients with MDR-TB being transferred to referral hospitals. In this study, the drug resistance trends for first-line drugs or any drug significantly decreased, (also noted in northern and southern Taiwan). 12, 13 As expected, the resistance rate observed in this study was higher in previously treated patients (p < 0.05), as reported previously. 14, 16, 17 The resistance rate to any drug was similar in men and women, but men were more likely to have MDR-TB than women, which is different to results in previous studies. [17] [18] [19] We found that age was a significant factor in the development of drug resistance. Younger patients showed higher resistance rates than those ≥ 65 years. Resistance to any drug was highest in those aged 45-64 years, and those aged 25-44 years had the highest rate of MDR. WHO mentioned that MDR-TB was likely to be associated with male sex and a younger age group (25-44 years). 2 Our data show similar results.
There may be many factors contributing to these age and sex differences, e.g. the year in which they received effective anti-TB drug 20 or patient compliance.
The association between TB and HIV/acquired immunodeficiency syndrome (AIDS) has frequently been discussed. The prevalence of HIV infection in new TB cases varies between regions and countries: from 1% in the Western Pacific region to 38% in the African region. Nine percent (7-12%) of all new TB cases in adults aged 15-49 years are attributable to HIV infection. 21 4 A recent study from a medical center in northern Taiwan reported that the prevalence of HIV infection among TB patients was 5.6%. 24 As previously mentioned, 222/1,961 TB patients were tested for HIV. Of these, 3.2% were HIV positive, while the HIV prevalence rate among the TB patients reported by the CDC was 0.7%. There were 1,739 (1,961 minus 222) untested patients, which may have resulted in higher rates of HIV diagnosis. The increase in suspected cases may have been 55 (1,739 multiplied by 3.2%) or seven (1,739 multiplied by 0.7%). Thus HIV screening is very important in TB cases.
This study had some limitations. First, the method used for AST was different before March 2005. As a result, the critical concentrations of INH and streptomycin were not the same. Second, as this was a retrospective study, some data may be incomplete.
In conclusion, this study shows a significant decrease in drug resistant TB from 2003 to 2007. As expected, resistance to anti-TB drugs was associated with previous episodes of anti-TB treatment. Although DOTS may have been effective in controlling TB, MDR-TB remains a challenge.
